Renal and liver injury following the treatment of covid-19 by remdesivir
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19
Tag: Covid-19
Thapsigargin repurposing for COVID-19
Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for
A polypeptide, Plitidepsin has potent preclinical efficacy against SARS-CoV-2
The science reported that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold
Novel drug for oral treatment against Covid-19
Nature Microbiology reported on an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801, that was repurposed for use against
Global Alpha-Cyclodextrin Market Outlook And Regional Analysis with Impact Analysis of COVID-19 (2021-2030)
APNEWS reported: This exhaustive Alpha-Cyclodextrin market report provides a full holistic analysis [2012-2019], market size and time frame [2021-2030], emerging
Utility of aspirin in hospitalized COVID-19 patients
A recent paper published in Anesthesia & Analgesia Journal evaluated the possible benefits of using aspirin in hospitalized COVID-19 patients
Alpha-CD-containing oral spray to inhibit the SARS-CoV-2 endocytosis
Italian researchers developed an oral spray (Endovir Stop) containing alpha-cyclodextrin (0.2%) and hydroxytyrosol (3.8%) for the improvement of the defenses
FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Pfizer and BioNTech announced vaccine candidate against covid-19 achieved success in first interim analysis from Phase 3 study
Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective Pfizer and BioNTech announced on 09 October their mRNA-based vaccine
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s